Clearside Biomedical to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update on Wednesday,...
February 24 2021 - 7:05AM
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical
company dedicated to developing and delivering treatments that
restore and preserve vision for people with serious back of the eye
diseases, announced today that its fourth quarter and full year
2020 financial results will be reported on Wednesday, March 10,
2021 after the close of the financial markets. Management will host
a webcast and conference call at 4:30 p.m. Eastern Time to discuss
the results and provide a corporate update.
The live and archived webcast may be accessed on
the Clearside website under the Investors section: Events and
Presentations. The live call can be accessed by dialing (844)
263-8310 (domestic) or (213) 358-0959 (international) and entering
conference code: 5286349. An archive of the webcast will be
available for three months.
About Clearside Biomedical
Clearside Biomedical, Inc. is a
biopharmaceutical company dedicated to developing and delivering
treatments that restore and preserve vision for people with serious
back of the eye diseases. Clearside’s proprietary SCS
Microinjector® targets the suprachoroidal space (SCS®) and offers
unique access to the macula, retina and choroid where
sight-threatening disease often occurs. The Company’s SCS injection
platform is an inherently flexible, in-office, non-surgical
procedure, intended to provide targeted delivery to the site of
disease and to work with both established and new formulations of
medications, as well as future therapeutic innovations. For more
information, please visit www.clearsidebio.com.
Investor and Media Contacts:Jenny Kobin Remy
Bernarda ir@clearsidebio.com(678) 430-8206
Source: Clearside Biomedical, Inc.
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Sep 2023 to Sep 2024